Loss-of-function variants in ITSN1 confer high risk of Parkinson’s disease

Parkinson's disease (PD) is a debilitating neurodegenerative disorder and its rising global incidence highlights the need for the identification of modifiable risk factors. In a gene-based burden test of rare variants (8647 PD cases and 777,693 controls) we discovered a novel association between loss-of-function variants in ITSN1 and PD. This association was further supported with burden data from the Neurodegenerative Disease Knowledge Portal and the Accelerating Medicines Partnership Parkinson's Disease Knowledge Platform. Our findings show that Rho GTPases and disruptions in synaptic vesicle transport may be involved in the pathogenesis of PD, pointing to the possibility of novel therapeutic approaches.

Authors

Institutions

Publication Details

Journal
npj Parkinson s Disease
Published
2024-08-15
DOI
https://doi.org/10.1038/s41531-024-00752-9
Citations
11
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
6.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Loss-of-function variants in ITSN1 confer high risk of Parkinson’s disease

Árni Sturluson, Pálmi V. Jónsson, Hreinn Stefánsson, Guðrún A. Jónsdóttir et al.
11 citations
npj Parkinson s Disease
Genomics and Rare Diseases
6.05
article

Loss-of-function variants in ITSN1 confer high risk of Parkinson’s disease

Árni Sturluson, Pálmi V. Jónsson, Hreinn Stefánsson, Guðrún A. Jónsdóttir, G. Bragi Walters, Kāri Stefánsson, Hannes Helgason, Thorgeir E. Thorgeirsson, Sigurjón A. Guðjónsson, Ólafur Sveinsson, Daníel F. Guðbjartsson, Gyða Björnsdóttir, Erna V. Ivarsdottir, Anna Bjornsdottir, Arni F. Gunnarsson, Patrick Sulem, Brynjar Ö. Jensson, Vinicius Tragante, Vala Palmadottir, Rósa S. Gísladóttir, Ástrós Skúladóttir, Hilma Hólm, Garðar Sveinbjörnsson
article en
11 citations

Abstract

Parkinson's disease (PD) is a debilitating neurodegenerative disorder and its rising global incidence highlights the need for the identification of modifiable risk factors. In a gene-based burden test of rare variants (8647 PD cases and 777,693 controls) we discovered a novel association between loss-of-function variants in ITSN1 and PD. This association was further supported with burden data from the Neurodegenerative Disease Knowledge Portal and the Accelerating Medicines Partnership Parkinson's Disease Knowledge Platform. Our findings show that Rho GTPases and disruptions in synaptic vesicle transport may be involved in the pathogenesis of PD, pointing to the possibility of novel therapeutic approaches.

npj Parkinson s DiseaseVol. 10(1)
Reykjavík University (IS), deCODE Genetics (Iceland) (IS), University of Iceland (IS), National University Hospital of Iceland (IS)
Foundation for the National Institutes of Health, U.S. Department of Health and Human Services, Michael J. Fox Foundation for Parkinson's Research, Pfizer, GlaxoSmithKline, Sanofi, Celgene, Verily Life Sciences, National Institutes of Health, National Institute of Neurological Disorders and Stroke
Partnerships for the goals
Openalex Percentile: Top 3%
Genomics and Rare Diseases
6.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.